vimarsana.com

Page 29 - சிங்கப்பூர் ஜநரல் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lee Wanta, American Hero – Veterans Today | Military Foreign Affairs Policy Journal for Clandestine Services

Lee Wanta, American Hero – Veterans Today | Military Foreign Affairs Policy Journal for Clandestine Services
veteranstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from veteranstoday.com Daily Mail and Mail on Sunday newspapers.

New study launched to more accurately diagnose early hepatocellular carcinoma

New study launched to more accurately diagnose early hepatocellular carcinoma A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual s likelihood of developing the cancer. HCC is the sixth most common cancer in the world but the third most common cause of cancer deaths globally. In Singapore, HCC is the third and fourth most common cause of cancer deaths, amongst males and females respectively. While potentially curative treatment is possible with early diagnosis, only 20% of HCC cases are detected at a stage where cure is possible. This investigator-initiated multi-centre study led by the National Cancer Centre of Singapore (NCCS) called EarLy DEtection of HCC: miRNA, microbiome and imaGing biomArkers in the evolution of chroNiC livEr Disease in a high-risk prospective cohort (ELEGANCE), addresses thi

Landmark study launched to detect liver cancer early in Singapore

 E-Mail IMAGE: Quantitative MR images of the liver from six patients presenting with liver cancer produced by Perspectum s LiverMultiScan which will be used in a new study led by National Cancer Centre. view more  Credit: Image credit: Mole DJ et al. Plos One. 2020;15(12):e0238568 Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need. Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual s risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.

NTU Singapore scientists invent catheter system to deliver electricity-activated glue path

Loading video. VIDEO: A team of researchers led by Nanyang Technological University, Singapore (NTU Singapore) has developed a device that offers a quicker and less invasive way to seal tears and holes in. view more  Credit: NTU Singapore A team of researchers led by Nanyang Technological University, Singapore (NTU Singapore) has developed a device that offers a quicker and less invasive way to seal tears and holes in blood vessels, using an electrically-activated glue patch applied via a minimally invasive balloon catheter. This device could eventually replace the need for open or keyhole surgery to patch up or stitch together internal blood vessel defects.

Landscape study launched to detect liver cancer early in Singapore

 E-Mail IMAGE: Quantitative MR images of the liver from six patients presenting with liver cancer produced by Perspectum s LiverMultiScan which will be used in a new study led by National Cancer Centre. view more  Credit: Mole DJ et al. Plos One. 2020;15(12):e0238568 Singapore, 3 May 2021 - A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual s likelihood of developing the cancer. HCC is the sixth most common cancer in the world but the third most common cause of cancer deaths globally.[1] In Singapore, HCC is the third and fourth most common cause of cancer deaths, amongst males and females respectively.[2] While potentially curative treatment is possible with early diagnosis, only 20% of HCC cases are detected at a stage where cure is possible. This investigator-initiated multi-centre s

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.